Indications
Scedosporiosis and fusariosis
Voriconazole is an azole antifungal medicine. It is indicated for use in patients 12 years of age and older in the treatment of following fungal infections-
Invasive aspergillosis
Candidemia (nonneutropenic) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds
... Read more
Voriconazole is an azole antifungal medicine. It is indicated for use in patients 12 years of age and older in the treatment of following fungal infections-
Invasive aspergillosis
Candidemia (nonneutropenic) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds
Esophageal candidiasis
Serious infections caused by Scedosporium apiospermum and Fusarium Species including Fusarium solani
Patients intolerant of, or refractory to other therapy.
Dosage And Administration
Oral-
Voriconazole tablet and powder for suspension are to be taken at least one hour before or one hour following a meal
At or over 40 kg body weight: Loading dose regimen is 400 mg or 10 ml every 12 hours (for the first 24 hours) and maintenance dose (after first 24 hours) is 200 mg or 5 ml twice daily.
Below 40 Kg body weight: Loading dose regimen is 200 mg or 5 ml every 12 hours (for the first 24 hours) and maintenance dose (after first 24 hours) is 100 mg or 2.5 ml twice daily. Or, as directed by the registered physician.
Injection-
Invasive Aspergillosisd :
Loading dose: 6 mg/kg 12 hourly for the first 24 hours.
Maintenance Dose: 4 mg/kg 12 hourly.
Candidemia in nonneutropenic patients and other deep tissue Candida infections:
Loading dose: 6 mg/kg 12 hourly for the first 24 hours.
Maintenance Dose: 3-4 mg/kg 12 hourly.
Scedosporiosis and Fusariosis:
Loading dose: 6 mg/kg 12 hourly for the first 24 hours.
Maintenance Dose: 4 mg/kg 12 hourly.
Side Effects
The most common side effects are abdominal pain, anemia, blurred vision, headache, chest pain, nausea and diarrhea.
Precautions And Warnings
Long term exposure (treatment or prophylaxis) greater than 180 days requires careful assessment of the benefit-risk balance. Squamous cell carcinoma of the skin (SCC) has been reported in relation with long-term voriconazole treatment.
Pregnancy And Lactation
There are no adequate and well-controlled studies in pregnant woman. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.